Kodiak Sciences has patented a method for treating eye disorders, specifically wet age-related macular degeneration, using an anti-VEGF antibody conjugate. Administering three loading doses extends the therapeutic effect for at least 12 weeks, offering a less frequent treatment option for patients. GlobalData’s report on Kodiak Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kodiak Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kodiak Sciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Kodiak Sciences's grant share as of February 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Treating eye disorder with anti-vegf antibody conjugate

Source: United States Patent and Trademark Office (USPTO). Credit: Kodiak Sciences Inc

A recently granted patent (Publication Number: US11912784B2) discloses a method for treating eye disorders, specifically wet age-related macular degeneration (wAMD), using an anti-VEGF antibody conjugate. The method involves administering three loading doses of the conjugate to a subject, with the heavy chain of the antibody conjugate containing specific amino acid sequences and a phosphorylcholine containing polymer covalently bonded to it. The therapeutic result of the treatment is expected to last for at least 12 weeks after the final loading dose, with subsequent doses administered based on the outcome of assessment tests for ocular health and function. The dosing schedule is designed to ensure the treatment is not administered more frequently than once a month, with the aim of modifying the eye disorder in a beneficial manner to the subject.

Furthermore, the patent claims detail various aspects of the treatment method, including the duration of the therapeutic result lasting up to 20 weeks post final loading dose, the administration of subsequent doses at specific time intervals, and the specific structure of the antibody conjugate. The method also emphasizes the importance of the dosing schedule, with doses not exceeding once every 24 weeks on average. The treatment aims to improve visual acuity, reduce retinal thickness, enhance perfusion in the eye, and reduce disease activity related to the eye disorder. Administered via intravitreal injection, the method provides a detailed framework for effectively treating and modifying eye disorders, particularly wAMD, in patients requiring such intervention.

To know more about GlobalData’s detailed insights on Kodiak Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies